左旋棉酚联合低浓度阿霉素诱导软组织肉瘤细胞凋亡及其作用机制的实验研究
|
摘要
目的：研究左旋棉酚联合低浓度阿霉素对软组织肉瘤人纤维肉瘤HT1080细胞和滑膜肉瘤SW982细胞的凋亡及其作用机制,为提高肿瘤治疗效果提供理论依据。方法：采用MTT法检测药物对肿瘤细胞的抗增殖作用,应用Wright-Giemsa染色、Hoechst 33258染色、透射电镜观察药物作用后肿瘤细胞的形态学变化,琼脂糖凝胶电泳分析药物作用后肿瘤细胞DNA有无出现梯状带型,用流式细胞仪检测药物作用后肿瘤细胞的凋亡率和细胞周期的变化。Western-Blot法检测药物作用后肿瘤细胞凋亡相关基因Bcl-2、Bax蛋白的表达,比色分析法测定药物作用后肿瘤细胞内Caspase-3和Caspase-9的活性变化。结果：左旋棉酚与低浓度阿霉素对软组织肉瘤人纤维肉瘤HT1080细胞和滑膜肉瘤SW982细胞具有抑制增殖作用,联合应用抑制增殖作用更强,具有浓度与时间依赖性。左旋棉酚与低浓度阿霉素能诱导软组织肉瘤人纤维肉瘤HT1080细胞和滑膜肉瘤SW982细胞凋亡,两药作用后肿瘤细胞出现典型的凋亡细胞所具有的特征性改变,DNA琼脂糖凝胶电泳观察到明显的梯状带型,流式细胞仪检测发现左旋棉酚与低浓度阿霉素能诱导肿瘤细胞凋亡,联合应用作用更强。左旋棉酚与低浓度阿霉素对软组织肉瘤人纤维肉瘤HT1080细胞和滑膜肉瘤SW982细胞具有细胞周期调节作用,左旋棉酚使细胞阻滞在G1期,阿霉素使细胞阻滞在S期,两药联合应用使S期明显增加。左旋棉酚与低浓度阿霉素均导致肿瘤细胞Bcl-2蛋白表达逐渐减少,Bax蛋白的表达逐渐增多,两药联合应用变化更加明显。在诱导肿瘤细胞凋亡的过程中,肿瘤细胞内出现Caspase-9、Caspase-3的活化,两药联合应用变化更加明显。结论：左旋棉酚与低浓度阿霉素对软组织肉瘤人纤维肉瘤HT1080和滑膜肉瘤SW982细胞有明显抑制增殖及诱导凋亡作用,联合应用作用更强,其机制可能与下调Bcl-2蛋白表达,上调Bax蛋白表达及影响细胞周期有关。本研究通过左旋棉酚与低浓度阿霉素联合应用的体外实验,探讨了其治疗软组织肉瘤的可行性及其相互作用机理,为筛选与阿霉素有效配伍的抗肿瘤药物提供了实验依据。
Objective:To investigate Apoptosis Inducted by (-)-Gossypo with combination of low concentration of adriamycin in soft tissue sarcoma cells and Its Mechanisms, offer theoretical basis for the improvement of cancer treatment. Methods:The antiproliferation of drugs on cells was deteceted by MTT assay. The changes of cells morphology and quantity were observed by Wright-Giemsa staining、Hoechst 33258 staining and transmission electron microscopy. DNA ladder formation was determined in Agarose gel electrophoresis.The apoptosis rate and cell cycle of soft tissue sarcoma cells treated by drugs was detected by flow cytometry. And the protein expression of Bcl-2、Bax in soft tissue sarcoma cells treated by drugs were detected by Western-Blot. The changes of caspase-3 and caspase-9 was deteceted by colorimetric assay. Results:(-)-Gossypol and low concentration of adriamycin resulted in a dose and time dependent ihnibition of HT1080 and SW982 cells,(-)-Gossypo with combination of low concentration of adriamycin had more obviouse effet of antiporliefration.(-)-Gossypol and low concentration of adriamycin was found to be bale to induce apoptosis of HT1080 and SW982 cells, as evidenced by typical morphological changes. Agarose gel electrophoresis determined typical DNA ladder formation.Flow cytometry deteceted that (-)-gossypol and low concentration of adriamycin induce apoptosis of HT1080 and SW982 cells (-)-Gossypo with combination of low concentration of adriamycin had more obvious apoptosis-inducing effet. Cell cycle analysis by flow eytometry indicated that (-)-Gossypol and low concentration of adriamycin could change cell cycle.(-)-Gossypol can induce G1 arrest and low concentration of adriamycin can induce S arrest.(-)-Gossypo with combination of low concentration of adriamycin had more obvious increace of S arrest,which evidence that (-)-Gossypol increased the chemotherapy sensitivity of HT1080 and SW982 cells.(-)-Gossypol and low concentration of adriamycin can result in decrease of the protein expression level of Bcl-2 and decrease of the protein expression level of Bax.The combination had more obvious changes. Colorimertie assay showed an activation of caspase-9 and caspase-3. The combination had higher activation changes.Conclusion: In this sutdy,we showed that (-)-Gossypol and low concentration of adriamycin had the effet of antiprolierfation and inducetion of apoptosis on HT1080 and SW982 cells for the first time.(-)-Gossypo with combination of low concentration of adriamycin had more obvious effect. The mechanisms mihgt involve down-relulation of Bcl-2 and up-relulation of bax and affeting cell cycle. Experimental Study on (-)-Gossypo with combination of low concentration of adriamycin in vitro discuss feasibility and interactional mechanism on the effect of (-)-Gossypo with combination of low concentration of adriamycin in soft tissue sarcoma and provide Experimental evidence for screen effective antitumor drugs combining with adriamycin.
Objective:To investigate Apoptosis Inducted by (-)-Gossypo with combination of low concentration of adriamycin in soft tissue sarcoma cells and Its Mechanisms, offer theoretical basis for the improvement of cancer treatment. Methods:The antiproliferation of drugs on cells was deteceted by MTT assay. The changes of cells morphology and quantity were observed by Wright-Giemsa staining、Hoechst 33258 staining and transmission electron microscopy. DNA ladder formation was determined in Agarose gel electrophoresis.The apoptosis rate and cell cycle of soft tissue sarcoma cells treated by drugs was detected by flow cytometry. And the protein expression of Bcl-2、Bax in soft tissue sarcoma cells treated by drugs were detected by Western-Blot. The changes of caspase-3 and caspase-9 was deteceted by colorimetric assay. Results:(-)-Gossypol and low concentration of adriamycin resulted in a dose and time dependent ihnibition of HT1080 and SW982 cells,(-)-Gossypo with combination of low concentration of adriamycin had more obviouse effet of antiporliefration.(-)-Gossypol and low concentration of adriamycin was found to be bale to induce apoptosis of HT1080 and SW982 cells, as evidenced by typical morphological changes. Agarose gel electrophoresis determined typical DNA ladder formation.Flow cytometry deteceted that (-)-gossypol and low concentration of adriamycin induce apoptosis of HT1080 and SW982 cells (-)-Gossypo with combination of low concentration of adriamycin had more obvious apoptosis-inducing effet. Cell cycle analysis by flow eytometry indicated that (-)-Gossypol and low concentration of adriamycin could change cell cycle.(-)-Gossypol can induce G1 arrest and low concentration of adriamycin can induce S arrest.(-)-Gossypo with combination of low concentration of adriamycin had more obvious increace of S arrest,which evidence that (-)-Gossypol increased the chemotherapy sensitivity of HT1080 and SW982 cells.(-)-Gossypol and low concentration of adriamycin can result in decrease of the protein expression level of Bcl-2 and decrease of the protein expression level of Bax.The combination had more obvious changes. Colorimertie assay showed an activation of caspase-9 and caspase-3. The combination had higher activation changes.Conclusion: In this sutdy,we showed that (-)-Gossypol and low concentration of adriamycin had the effet of antiprolierfation and inducetion of apoptosis on HT1080 and SW982 cells for the first time.(-)-Gossypo with combination of low concentration of adriamycin had more obvious effect. The mechanisms mihgt involve down-relulation of Bcl-2 and up-relulation of bax and affeting cell cycle. Experimental Study on (-)-Gossypo with combination of low concentration of adriamycin in vitro discuss feasibility and interactional mechanism on the effect of (-)-Gossypo with combination of low concentration of adriamycin in soft tissue sarcoma and provide Experimental evidence for screen effective antitumor drugs combining with adriamycin.
引文
[1]Nielsen OS, Judson I, Van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas:a multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group[J]. Eur J Cancer,2000,36(1):61-67.
[2]Iagaru A, Quon A, McDougall IR, et al. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas[J]. Clin Nucl Med,2006,31:754-760.
[3]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2008. CA Cancer J Clin 2008, 58:71-96.
[4]Fang Z W, Cheng J, Teng S, et al. Analysis of soft tissue sarcomas in 1118 cases[J]. Chinese Medical Journal,2009,122(1):51-53.
[5]Seidel C, Bartel F, Rastetter M, et al. Alterations of cancer-related genes in soft tissue sarcomas:hypermethylation of RASSF1A is frequently detectedin leiomyo sarcoma and associated with poor prognosis in sarcoma[J]. Int J Cancer,2005,114:442-447.
[6]van de Rijn M, Fletcher JA. Genetics of soft tissue tumors[J]. Annu Rev Pathol,2006, 1:435-466.
[7]Kasper B, Gil T, D'Hondt V, et al. Novel treatment strategies for soft tissue sarcoma[J]. Grit Rev Oncol Hematol,2007,1:9-15.
[8]郭全义,卢世璧,张莉,等.骨肉瘤的治疗及生存率的多因素分析[J].中国矫形外科杂志,2006,7：497-499.
[9]Mitsuyasu RT.AIDS-related Kaposips sarcoma:Current treatment, future trends[J].Oncology,2000,14(6):867-878.
[10]Okuno S, Ryan LM, et al.Phase 11 trial of gemcitabine in patients with advanced sarcomas (E1797)[J].Cancer,2003,15,97(8):1969-1973.
[11]Dhillon T, Stebbing J, Bower M.Paclitaxel for AIDS associated Kaposi's sarcoma[J]. Expert Rev Anticancer Ther,2005,5(2):215-219.
[12]Lim ST, Tupule A, Espina BM, et al.Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome related Kaposi sarcoma[J]. Cancer,2005,103(2):417-421.
[13]Bernbeck B, Bahci S, Meisel R, et al.Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with highrisk soft tissue sarcoma[J]. Klin Padiatr,2007,219(6):318-322.
[14]Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma[J]. Cancer,2006, 106(3):703-707.
[15]Garcia Del MX, Fra J, Martinez TJ, et al. Temozolomide in the treatment of gynecological leiomyosarcoma:a Spanish Group for Research on Sarcomas(GEIS) study[C]. Symposium of ASCO,2005:a9030.
[16]Hartmann JT. A non-comparative phase II study of pemetrexed in Patients with pretreated soft tissue sarcoma[J]. J Clin Oncol,2008:al0575.
[17]Garcia Carbonero R, Supko JG, Maki RG, et al. Ectemascidin2743(ET2743) for chemotherapy naive patients with advanced soft tissue sarcomas:multicenter phase II and pharmacokinetic study[J]. J Clin Oncol,2005,23(24):5484-5492.
[18]Macap inlacM, Elrafei T, Cunningham I, et al.Dermatto fibrosarcoma protuberans: neoadjuvant therpy with imatinib mesylate anduse of plasma PDGF-βlevels to monitor clinical response[C]. Symposium of ASCO,2004:a9049.
[19]Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas:Update of phase II trial[C]. Symposium of ASCO,2007:al 0076.
[20]D Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas[J]. J Clin Oncol,2005, 23:7135-7142.
[21]Maki RG. Updated results of a phase II study of oral multikinase inhibitor sorafenib in sarcomas[C]. Symposium of ASCO,2008:al0531.
[22]Vigil CE, Chiappori AA. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectabl enon-GIST soft tissue sarcomas[C]. Symposium of ASCO,2008:al0535.
[23]Olmos D, Okuno S. Safety, pharmacokinetics and preliminary activity of the anti-IGFIR antibody CP-751,871 in sarcoma patients[C]. Symposium of ASCO, 2008:al0501.
[24]方志伟.软组织肉瘤治疗的现状与展望[J].中华肿瘤防治杂志,2009,16(4)：241-245.
[25]Scurr M, Judson I. Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. Hematol Oncol Clin North Am 2005; 19:489-500.
[26]Chen Defu, Li Rui, Liang Yan, et al. Preliminary study on the effect of arsenictrioxide on malignant lymphoma cell lines[J]. Tianjin Med J,2003,31(4):210-213.
[27]Dodou K, Anderson RJ, Small DA, et al. Investigations on gossypol:past and present developments[J]. Expert Op in Investig Drugs,2005,14(11):1419-1434.
[28]Coutinho EM, Athayde C, Atta G. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. Amulticenter, international, dose-finding study[J]. Contraception,2000,6(1):61-67.
[29]Meng Y, Li Y, Li J, et al. (-)-Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells[J]. Leuk Lymphoma,2007, 48(11):2204-2212.
[30]Ko CH, Shen SC, Yang LY, et al. Gossypol reduction of tumor growth through ROS dependent mitochondria pathway in human colorectal carcinoma cells[J]. Int J Cancer, 2007,121(8):1670-1679.
[31]Huang YW, Wang LS, Chang HL, et al. Effects of serumon (-)-gossypol-suppressed growth in human prostate cancer cells[J]. Anticancer Res,2006,26(5):3613-3620.
[32]Wolter KG, Wang SJ, Henson BS, et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo[J]. Neoplasia, 2006,8(3):163-172.
[33]Kitada S, Kress CL, Jia L, et al. Bcl-2 antagonist ApoGossypol(NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with lesstoxicity compared to Gossypol(NSC19048)[J]. Blood,2008,11(6):3211-3219.
[34]Ye W, Chang HL, Wang LS, et al. Modulation of multidrug resistance gene expression in human breast cancer cells by gossypol-enriched cottonseed oil[J]. Anticancer Res,2007,27(1):107-116.
[35]Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-x(1) [(-)-gossypol] aginst diffuse large cell limphoma[J]. Mol Cancer Ther,2005,4(1):13-21.
[36]Reed JC. Pro-apoptotic multidomain Bcl-2/Bax family proteins:mechanisms, physiological roles, and therapeutic opportunities [J]. Cell Death Differ,2006,13(8):1 378-1386.
[37]Rezende AC, Vieira AS, Rogerio FRezende LF, et al. Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection[J]. Braz J Med BiolRes, 2008,41:1024-1028.
[38]Cory S, Huang DC, Adams JM. The Bcl-2 family:roles in cell survival and oncogenesis[J]. Oncogene,2003,22(53):8590-8607.
[39]Tan C, Dlugosz PJ, Peng J, et al. Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2[J]. J Biol Chem,2006,281(21):14 764-14 775.
[40]Logan Banadyga, Kirstin Veugelers, Stephanie Campbell, et al. The Fowlpox Virus BCL-2 Homologue, FPV039, Interacts with Activated Bax and a Discrete Subset of BH3-Only Proteins To Inhibit Apoptosis[J]. Journal of Virology,2009,83(14):7085-7 098.
[41]Rezende AC, Vieira AS, Rogerio F, et al. Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection[J]. Braz J Med BiolRes,2008,41:1024-1028.
[42]Morissette MC, Vachon-Beaudoin G, Parent J, et al. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expressionin human emphysema[J]. Am J Respir Crit Care Med,2008,178:240-247.
[43]Zhang Z, Zhu WJ, Suzanne M. Lapolla, et al. Bax Forms an Oligomer via Separate, Yet Interdependent, Surfaces[J]. J Biol Chem,2010,285:17 614-17 627.
[44]Antignani A, Youle RJ. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?[J]. Curr Opin Cell Biol,2006,18(6):685-689.
[45]Er E, Oliver L, Cartron PF, et al. Mitochondria as the target of the proapoptotic protein Bax[J]. Biochim Biophys Acta,2006,1757(9-10):1301-1311.
[46]Yao MZ, Nguyen TV, Pike C, et al. β-Amyloid-induced neuronal apoptosis involvescjun N-terminal kinase dependent downregulation of Bcl-w[J]. J Neur,2005, 25(5):1149-1158.
[47]Reed JC. Pro-apoptotic multidomain Bcl-2/Bax family proteins:mechanisms, physiological roles, and therapeutic opportunities[J]. Cell Death Differ,2006,13(8):1 378-1386.
[48]Kukreja RC, Xi L.eNOS phosphorylation:a pivotal molecular switch in vasodilation and cardioprotection?[J].J Mol Cell Cardiol,2007,42 (2):280-282.
[49]Bajt ML, Farhood A, Lemasters JJ, et al. Mitochondrial bax translocation accelerates DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity[J]. J Pharmacol Exp Ther,2007,324(1):8-14.
[50]Tikhomirov O, Carpenter G. Bax activation and translocation to mitochondria mediate EGF induced programmed cell death[J]. J Cell Sci,2005,118(24):5681-5690.
[51]Deep G, Singh RP, Agarwal C, et al. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells:a comparison of flavanone silibinin with flavanolignan mixture silymarin[J]. Oncogene,2006,25:1 053-1069
[52]林洁,武永吉,杨大俊,等. Apogossypolone诱导骨髓瘤细胞凋亡及其机制研究[J].中国实验血液学杂志,2009,17(1)：92-98.
[53]牛晓阁,汪森明,丁为民,等. Apogossypolone抑制乳腺癌MCF-7细胞增殖及诱导细胞凋亡[J].肿瘤,2010,30(12)：1022-1 026
[54]Rathinasamy K, Jindal B, Asthana J, et al. Gesreiasrceh aortficulelvin stabilizes microtubu ledynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine[J]. BMC Cancer,2010,10:213-225.
[55]Shidaifat F, Canatan H, Kulp SK, et al. Gossypol arrests human benign prostatic hyperplastic cell growth at GO/Glphase of the cell cycle[J]. Anticancer Res,1997, 17(2A):1003-1009
[56]Wang X,Wang J,Wong SC, et al.Cytotoxic effct of apogossy on colon Carcinoma cells[J].Life Sci,2000,67:2663-2671.
[1]Dodou K, Anderson RJ, Small DA, et al. Investigations on gossypol:past and present developments[J]. Expert Opin Investig Drugs,2005,14(11):1419-1434.
[2]Blackstaffe L, Shelley MD, Fish RG. Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone inmelanoma cell lines[J]. MelanomaRes,1997, 7(5):364-372.
[3]Coutinho EM, Athayde C, Atta G. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. Amulticenter, international, dose-finding study[J]. Contraception,2000,6(1):61-67.
[4]Yu ZH, Chan HC. Gossypol as a male antifertility agent why studies should have been continued[J].Int J Androl,1998,21(1):2-7.
[5]Vanpoznak C, Seidman AD, Reidenbergm M, et al.Oral gossypol in the treatment of patientswith refractory metastatic breast cancer:a phase I/II clinical trial [J]. Breast Cancer Restreat,2001,66(3):239-248.
[6]Shelley MD, Hartley L, Fish RG, et al. Stereospecific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines[J]. Cancer Letters,1999, 135(2):171-180
[7]Rekha GK, Sladek NE. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol[J].Adv Exp Med Biol,1997414:133-146
[8]Coyle T, Levante S, Shetler M, et al. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines[J].J Neurooncol,1994,19(1)25-35
[9]Hutchinson RW, Ing NH, Burghardt RC. Induction of c-fos, and cytochrome coxidase subunits I and II by gossypol acetic acid in rat liver cells[J]. Cell Biol Toxicol,1998, 14(6):391-399
[10]McManus M, Serhan C, Jackson P, et al. Ketoconazole blocks organic osmolyte efflux independently of its effect on arachidonic acid conversion[J]. Am J Physiol, 1994,267(1 Ptl):C266-271
[11]Shidaifat F, Canatan H, Kulp SK, et al. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle [J]. Anti cancer Res,1997, 17(2A):1003-1009
[12]Deep G, Singh RP, Agarwal C, et al. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human p rostate cancer PC3 cells:a comparison of flavanone silibinin with flavanolignan mixture silymarin[J]. Oncogene,2006,25:1 053-1069
[13]Ligueros M, Jeoung D, Tang B, et al. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells[J]. Br J Cancer,1997,76(1):21-28
[14]林洁,武永吉,杨大俊,等. Apogossypolone诱导骨髓瘤细胞凋亡及其机制研究[J].中国实验血液学杂志,2009,17(1)：92-98
[15]Van Poznak C, Seidman AD, Reidenberg M, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancerra phase I/II clinical trial[J]. Breast Cancer Res Treat,2001; 66:239-248
[16]Liu S, Kulp SK, Sugimoto Y, et al. The enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer[J]. Anticancer Res, 2002,22:33-38
[17]Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells[J]. Biochem Pharmacol,2003,66:93-103
[18]Zhang Y,Kulp SK,Sugimoto Y,et al. The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor betal production[J]. Int J Oncol,1998,13(6):1291-1297
[19]Jiang J, Sugimoto Y, Liu S, et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor betal (TGFbetal) signal transduction pathway[J]. Anticancer Res,2004,24(1):91-100.
[20]陈静坤,金毓翠,李慧芳,等.棉酚治疗子宫肌瘤的临床观察[J].上海第二医科大学学报,1997,17(1)：37-39
[21]Jarvis WD, Turner AJ, Povirk L F, et al. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C[J]. Cancer Res,1994,54(7):1707-1714
[22]Ye W, Chang HL, Wang LS, et al. Modulation of multidrug resistance gene expression in human breast cancer cells by gossypol-enriched cottonseed oil[J]. Anticancer Res,2007,27(1A):107-116.
[23]Celis J E,Celis A Cell cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells subdivision of S phase[J]. Proc Natl Ncad Sci U S A,1985,82:3262-3266.
[24]姜劲迈,张颖,叶百宽,等.棉酚抗癌作用机理研究[J].中国中医基础医学杂志,2002,8(2)：35-37.
[25]Oliver CL, Miranda MB, Shangary S, et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-X(L)-mediated apoptosis resistance[J]. Mol Cancer Ther,2005,4(1):23-31.
[26]Meng Y, Li Y, Li J. et al. (-)-Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells[J]. Leuk Lymphoma,2007, 48(11):2204-2212.
[27]Ko CH, Shen SC, Yang LY, et al. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells[J]. Int J Cancer,2007,121(8):1670-1679.
[28]Huang YW, Wang LS, Chang HL, et al. Effects of serumon (-)-gossypol-suppressed growth in human prostate cancer cells[J]. Anticancer Res,2006,26(5A):3613-3620.
[29]Wolter KG, Wang SJ, Henson BS, et al. Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo[J]. Neoplasia, 2006,8(3):163-172.
[30]Kitada S, Kress CL, Jia L, et al. Bcl-2 antagonist ApoGossypol(NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol(NSC19048)[J]. Blood,2008,111(6):3211-3219.
[31]王瑾,王向红,周淑雅,等.棉籽酚诱导结肠癌细胞系凋亡的作用[J].中国癌症杂志,2000,10(4)：319-322.
[32]Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small2molecule inhibitors of Bcl-2 through structure-based computer screening[J]. J Med Chem,2001,44:4314-4324
[33]Oliver CL, Miranda MB, Shangary S, et al. Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L)-mediated apoptosis resistance[J]. Mol Cancer Ther,2005,4(1):23-31.
[34]Wang X, Wang J, Wong SC, et al. Cytotoxic effect of gossypol on colon carcinoma cells[J]. Life Sci,2000,67(22):2 663-2 671.
[35]梁璐,汪森明,胡喜钢,等.醋酸棉酚对人鼻咽癌细胞凋亡的影响及其作用机制探讨[J].实用医学杂志,2008,24(7)：1 099-1 101
[36]田丹,汪森明,张积仁,等.醋酸棉酚对人宫颈癌细胞增殖的影响及其机制初探[J].解放军医学杂志,2008,33(9)：1 158-1 159
[37]杨金瑞,黄循,杨竹林,等.前列腺增生和前列腺癌组织细胞凋亡及Bcl-2,Bax基 因表达的研究[J].中华泌尿外科杂志,2000,8(21)：485-487.
[38]章劲夫,马杰,曹承华,等.醋酸棉酚诱导鼠前列腺癌细胞凋亡的研究[J].同济大学学报(医学版),2005,26(1)：26-29
[39]Mego M. Telomerase inhibitors in anticancer therapyrgossypol as a potential telomerase inhibitor [J]. Bratisl Lek Listy,2002,103(10):378-381.
[40]Teng CS. Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes[J]. Contracep tion,1995,52(6):389-395.
[41]Balci A, Sahin FI, Ekmekci A. Gossypol induced apoptosis in the human promyelocytic leukemia cell line HL60[J].Tohoku J Exp Med,1999,189(1):51-57.
[42]Carruthers NJ, Dowd MK, Stemmer PM. Gossypol inhibits calcineurin phosphatase activity at multiple sites[J]. Eur J Pharmacol,2007,555(2):106-114.
[43]Zhang M, Liu H, Guo R, et al. Molecularmechanism of gossypol induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells [J]. Biochem Pharmacol,2003,66(1):93-103.
[44]Ergun MA, Konac E, Erbasd, et al. Apoptosis and nitricoxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells[J]. Cell Biol Int,2004,28(3):237-242.
[45]Van Poznak C, Seidman AD, Reidenberg MM, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer:a phase I/II clinical trial [J]. Breast Cancer Res Treat,2001,66(3):239-248.
[46]Chang JS, Hsu YL, Kuo PL, et al. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line[J]. Clin Exp Pharmacol Physiol,2004,31(10):716-722.
[47]Veselska R, Zitterbart K, Auer J, et al. Differentiation of HL-60 myeloid leukemia cells induced by all trans retinoic acid is enhanced in combination with caffeic acid[J]. Int J MolMed,2004,14(2):305-310.
[48]张永清,黄高,陈协群,等.HL-60细胞定向分化时Bcl-2的表达[J].中华血液学杂志,2004,25(9)：569-571.
[49]王文清,黄高,梁蓉等,醋酸棉酚对白血病HL-60细胞凋亡及分化的影响,第四军医大学学报,2006；27(8)：733-736
[50]Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-x(1) [(-)-gossypol] aginst diffuse large cell limphoma[J]. Mol Cancer Ther,2005,4(1):13-21.
[51]Kasten-Pisula U, Windhorst S, Dahm-Daphi J, et al. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis[J]. Radiother Oncol,2007,83(3):296-303.
[52]Xu L,Yang D,Wang S, et al. Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer[J]. Mol Cancer Ther,2005, 4(2):197-205.
[53]Catherine VP, Andrew DS, Marcus MR, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer:A phase I/II clinical trial[J]. Breast Cancer Research and Treatment,2001,66(3):239-248.
[54]Bushunow P, Reidenberg MM, Wasenko J, et al. Gossypol treatment of recurrent adult malignant gliomas[J]. J Neurooncol,1999,43(1):79-86.
[55]Nielsen OS,Judson I,van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas:amulticent rephase II study of the EORTC Soft Tissue and Bone Sarcoma Group[J]. Eur J Cancer,2000,36(1):61-67.
[56]Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy [J]. Clin Oncol,2004,22(8):1480-1490.
[57]Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line t reatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J].J Clin Oncol,1995,13(7):1 537-1 545.
[58]Eemonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas[J]. J Clin Oncol,1993,11(7):1269-1275.
[59]Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults:the EORTC point of view[J]. Crit Rev Oncol/Hematol,1995,20:193-201.
[60]Schutte J, Kellner R, Seeber S. Ifosfamide in the treatment of soft tissue sarcomas: experience at the west german tumor center, Essen[J]. Cancer chemother pharmacol, 1993,31 (Supple2):s194-s198.
[61]Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma[J]. Crit Rev Oncol Hematol,2002,41 (2):157-167.
[62]Kasper B, Ho A D, Egerer G. Is there an indicaton for highdose chemotherapy in the treatment of bone and soft-tissue sarcoma?[J]. Oncology,2005,68(2-3):115-121.
[63]Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas[J]. J Clin Oncol,1993,11(7):1276-1285.
[64]Takeshita H, Kusuzaki K, Ashihara T, et al. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells. J Bone Joint Surg,2000,8(2A):963-969.
[2]Iagaru A, Quon A, McDougall IR, et al. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas[J]. Clin Nucl Med,2006,31:754-760.
[3]Jemal A, Siegel R, Ward E, et al. Cancer statistics,2008. CA Cancer J Clin 2008, 58:71-96.
[4]Fang Z W, Cheng J, Teng S, et al. Analysis of soft tissue sarcomas in 1118 cases[J]. Chinese Medical Journal,2009,122(1):51-53.
[5]Seidel C, Bartel F, Rastetter M, et al. Alterations of cancer-related genes in soft tissue sarcomas:hypermethylation of RASSF1A is frequently detectedin leiomyo sarcoma and associated with poor prognosis in sarcoma[J]. Int J Cancer,2005,114:442-447.
[6]van de Rijn M, Fletcher JA. Genetics of soft tissue tumors[J]. Annu Rev Pathol,2006, 1:435-466.
[7]Kasper B, Gil T, D'Hondt V, et al. Novel treatment strategies for soft tissue sarcoma[J]. Grit Rev Oncol Hematol,2007,1:9-15.
[8]郭全义,卢世璧,张莉,等.骨肉瘤的治疗及生存率的多因素分析[J].中国矫形外科杂志,2006,7：497-499.
[9]Mitsuyasu RT.AIDS-related Kaposips sarcoma:Current treatment, future trends[J].Oncology,2000,14(6):867-878.
[10]Okuno S, Ryan LM, et al.Phase 11 trial of gemcitabine in patients with advanced sarcomas (E1797)[J].Cancer,2003,15,97(8):1969-1973.
[11]Dhillon T, Stebbing J, Bower M.Paclitaxel for AIDS associated Kaposi's sarcoma[J]. Expert Rev Anticancer Ther,2005,5(2):215-219.
[12]Lim ST, Tupule A, Espina BM, et al.Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome related Kaposi sarcoma[J]. Cancer,2005,103(2):417-421.
[13]Bernbeck B, Bahci S, Meisel R, et al.Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with highrisk soft tissue sarcoma[J]. Klin Padiatr,2007,219(6):318-322.
[14]Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma[J]. Cancer,2006, 106(3):703-707.
[15]Garcia Del MX, Fra J, Martinez TJ, et al. Temozolomide in the treatment of gynecological leiomyosarcoma:a Spanish Group for Research on Sarcomas(GEIS) study[C]. Symposium of ASCO,2005:a9030.
[16]Hartmann JT. A non-comparative phase II study of pemetrexed in Patients with pretreated soft tissue sarcoma[J]. J Clin Oncol,2008:al0575.
[17]Garcia Carbonero R, Supko JG, Maki RG, et al. Ectemascidin2743(ET2743) for chemotherapy naive patients with advanced soft tissue sarcomas:multicenter phase II and pharmacokinetic study[J]. J Clin Oncol,2005,23(24):5484-5492.
[18]Macap inlacM, Elrafei T, Cunningham I, et al.Dermatto fibrosarcoma protuberans: neoadjuvant therpy with imatinib mesylate anduse of plasma PDGF-βlevels to monitor clinical response[C]. Symposium of ASCO,2004:a9049.
[19]Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas:Update of phase II trial[C]. Symposium of ASCO,2007:al 0076.
[20]D Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas[J]. J Clin Oncol,2005, 23:7135-7142.
[21]Maki RG. Updated results of a phase II study of oral multikinase inhibitor sorafenib in sarcomas[C]. Symposium of ASCO,2008:al0531.
[22]Vigil CE, Chiappori AA. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectabl enon-GIST soft tissue sarcomas[C]. Symposium of ASCO,2008:al0535.
[23]Olmos D, Okuno S. Safety, pharmacokinetics and preliminary activity of the anti-IGFIR antibody CP-751,871 in sarcoma patients[C]. Symposium of ASCO, 2008:al0501.
[24]方志伟.软组织肉瘤治疗的现状与展望[J].中华肿瘤防治杂志,2009,16(4)：241-245.
[25]Scurr M, Judson I. Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. Hematol Oncol Clin North Am 2005; 19:489-500.
[26]Chen Defu, Li Rui, Liang Yan, et al. Preliminary study on the effect of arsenictrioxide on malignant lymphoma cell lines[J]. Tianjin Med J,2003,31(4):210-213.
[27]Dodou K, Anderson RJ, Small DA, et al. Investigations on gossypol:past and present developments[J]. Expert Op in Investig Drugs,2005,14(11):1419-1434.
[28]Coutinho EM, Athayde C, Atta G. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. Amulticenter, international, dose-finding study[J]. Contraception,2000,6(1):61-67.
[29]Meng Y, Li Y, Li J, et al. (-)-Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells[J]. Leuk Lymphoma,2007, 48(11):2204-2212.
[30]Ko CH, Shen SC, Yang LY, et al. Gossypol reduction of tumor growth through ROS dependent mitochondria pathway in human colorectal carcinoma cells[J]. Int J Cancer, 2007,121(8):1670-1679.
[31]Huang YW, Wang LS, Chang HL, et al. Effects of serumon (-)-gossypol-suppressed growth in human prostate cancer cells[J]. Anticancer Res,2006,26(5):3613-3620.
[32]Wolter KG, Wang SJ, Henson BS, et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo[J]. Neoplasia, 2006,8(3):163-172.
[33]Kitada S, Kress CL, Jia L, et al. Bcl-2 antagonist ApoGossypol(NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with lesstoxicity compared to Gossypol(NSC19048)[J]. Blood,2008,11(6):3211-3219.
[34]Ye W, Chang HL, Wang LS, et al. Modulation of multidrug resistance gene expression in human breast cancer cells by gossypol-enriched cottonseed oil[J]. Anticancer Res,2007,27(1):107-116.
[35]Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-x(1) [(-)-gossypol] aginst diffuse large cell limphoma[J]. Mol Cancer Ther,2005,4(1):13-21.
[36]Reed JC. Pro-apoptotic multidomain Bcl-2/Bax family proteins:mechanisms, physiological roles, and therapeutic opportunities [J]. Cell Death Differ,2006,13(8):1 378-1386.
[37]Rezende AC, Vieira AS, Rogerio FRezende LF, et al. Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection[J]. Braz J Med BiolRes, 2008,41:1024-1028.
[38]Cory S, Huang DC, Adams JM. The Bcl-2 family:roles in cell survival and oncogenesis[J]. Oncogene,2003,22(53):8590-8607.
[39]Tan C, Dlugosz PJ, Peng J, et al. Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2[J]. J Biol Chem,2006,281(21):14 764-14 775.
[40]Logan Banadyga, Kirstin Veugelers, Stephanie Campbell, et al. The Fowlpox Virus BCL-2 Homologue, FPV039, Interacts with Activated Bax and a Discrete Subset of BH3-Only Proteins To Inhibit Apoptosis[J]. Journal of Virology,2009,83(14):7085-7 098.
[41]Rezende AC, Vieira AS, Rogerio F, et al. Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection[J]. Braz J Med BiolRes,2008,41:1024-1028.
[42]Morissette MC, Vachon-Beaudoin G, Parent J, et al. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expressionin human emphysema[J]. Am J Respir Crit Care Med,2008,178:240-247.
[43]Zhang Z, Zhu WJ, Suzanne M. Lapolla, et al. Bax Forms an Oligomer via Separate, Yet Interdependent, Surfaces[J]. J Biol Chem,2010,285:17 614-17 627.
[44]Antignani A, Youle RJ. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?[J]. Curr Opin Cell Biol,2006,18(6):685-689.
[45]Er E, Oliver L, Cartron PF, et al. Mitochondria as the target of the proapoptotic protein Bax[J]. Biochim Biophys Acta,2006,1757(9-10):1301-1311.
[46]Yao MZ, Nguyen TV, Pike C, et al. β-Amyloid-induced neuronal apoptosis involvescjun N-terminal kinase dependent downregulation of Bcl-w[J]. J Neur,2005, 25(5):1149-1158.
[47]Reed JC. Pro-apoptotic multidomain Bcl-2/Bax family proteins:mechanisms, physiological roles, and therapeutic opportunities[J]. Cell Death Differ,2006,13(8):1 378-1386.
[48]Kukreja RC, Xi L.eNOS phosphorylation:a pivotal molecular switch in vasodilation and cardioprotection?[J].J Mol Cell Cardiol,2007,42 (2):280-282.
[49]Bajt ML, Farhood A, Lemasters JJ, et al. Mitochondrial bax translocation accelerates DNA fragmentation and cell necrosis in a murine model of acetaminophen hepatotoxicity[J]. J Pharmacol Exp Ther,2007,324(1):8-14.
[50]Tikhomirov O, Carpenter G. Bax activation and translocation to mitochondria mediate EGF induced programmed cell death[J]. J Cell Sci,2005,118(24):5681-5690.
[51]Deep G, Singh RP, Agarwal C, et al. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells:a comparison of flavanone silibinin with flavanolignan mixture silymarin[J]. Oncogene,2006,25:1 053-1069
[52]林洁,武永吉,杨大俊,等. Apogossypolone诱导骨髓瘤细胞凋亡及其机制研究[J].中国实验血液学杂志,2009,17(1)：92-98.
[53]牛晓阁,汪森明,丁为民,等. Apogossypolone抑制乳腺癌MCF-7细胞增殖及诱导细胞凋亡[J].肿瘤,2010,30(12)：1022-1 026
[54]Rathinasamy K, Jindal B, Asthana J, et al. Gesreiasrceh aortficulelvin stabilizes microtubu ledynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine[J]. BMC Cancer,2010,10:213-225.
[55]Shidaifat F, Canatan H, Kulp SK, et al. Gossypol arrests human benign prostatic hyperplastic cell growth at GO/Glphase of the cell cycle[J]. Anticancer Res,1997, 17(2A):1003-1009
[56]Wang X,Wang J,Wong SC, et al.Cytotoxic effct of apogossy on colon Carcinoma cells[J].Life Sci,2000,67:2663-2671.
[1]Dodou K, Anderson RJ, Small DA, et al. Investigations on gossypol:past and present developments[J]. Expert Opin Investig Drugs,2005,14(11):1419-1434.
[2]Blackstaffe L, Shelley MD, Fish RG. Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone inmelanoma cell lines[J]. MelanomaRes,1997, 7(5):364-372.
[3]Coutinho EM, Athayde C, Atta G. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. Amulticenter, international, dose-finding study[J]. Contraception,2000,6(1):61-67.
[4]Yu ZH, Chan HC. Gossypol as a male antifertility agent why studies should have been continued[J].Int J Androl,1998,21(1):2-7.
[5]Vanpoznak C, Seidman AD, Reidenbergm M, et al.Oral gossypol in the treatment of patientswith refractory metastatic breast cancer:a phase I/II clinical trial [J]. Breast Cancer Restreat,2001,66(3):239-248.
[6]Shelley MD, Hartley L, Fish RG, et al. Stereospecific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines[J]. Cancer Letters,1999, 135(2):171-180
[7]Rekha GK, Sladek NE. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol[J].Adv Exp Med Biol,1997414:133-146
[8]Coyle T, Levante S, Shetler M, et al. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines[J].J Neurooncol,1994,19(1)25-35
[9]Hutchinson RW, Ing NH, Burghardt RC. Induction of c-fos, and cytochrome coxidase subunits I and II by gossypol acetic acid in rat liver cells[J]. Cell Biol Toxicol,1998, 14(6):391-399
[10]McManus M, Serhan C, Jackson P, et al. Ketoconazole blocks organic osmolyte efflux independently of its effect on arachidonic acid conversion[J]. Am J Physiol, 1994,267(1 Ptl):C266-271
[11]Shidaifat F, Canatan H, Kulp SK, et al. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle [J]. Anti cancer Res,1997, 17(2A):1003-1009
[12]Deep G, Singh RP, Agarwal C, et al. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human p rostate cancer PC3 cells:a comparison of flavanone silibinin with flavanolignan mixture silymarin[J]. Oncogene,2006,25:1 053-1069
[13]Ligueros M, Jeoung D, Tang B, et al. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells[J]. Br J Cancer,1997,76(1):21-28
[14]林洁,武永吉,杨大俊,等. Apogossypolone诱导骨髓瘤细胞凋亡及其机制研究[J].中国实验血液学杂志,2009,17(1)：92-98
[15]Van Poznak C, Seidman AD, Reidenberg M, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancerra phase I/II clinical trial[J]. Breast Cancer Res Treat,2001; 66:239-248
[16]Liu S, Kulp SK, Sugimoto Y, et al. The enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer[J]. Anticancer Res, 2002,22:33-38
[17]Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells[J]. Biochem Pharmacol,2003,66:93-103
[18]Zhang Y,Kulp SK,Sugimoto Y,et al. The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor betal production[J]. Int J Oncol,1998,13(6):1291-1297
[19]Jiang J, Sugimoto Y, Liu S, et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor betal (TGFbetal) signal transduction pathway[J]. Anticancer Res,2004,24(1):91-100.
[20]陈静坤,金毓翠,李慧芳,等.棉酚治疗子宫肌瘤的临床观察[J].上海第二医科大学学报,1997,17(1)：37-39
[21]Jarvis WD, Turner AJ, Povirk L F, et al. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C[J]. Cancer Res,1994,54(7):1707-1714
[22]Ye W, Chang HL, Wang LS, et al. Modulation of multidrug resistance gene expression in human breast cancer cells by gossypol-enriched cottonseed oil[J]. Anticancer Res,2007,27(1A):107-116.
[23]Celis J E,Celis A Cell cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells subdivision of S phase[J]. Proc Natl Ncad Sci U S A,1985,82:3262-3266.
[24]姜劲迈,张颖,叶百宽,等.棉酚抗癌作用机理研究[J].中国中医基础医学杂志,2002,8(2)：35-37.
[25]Oliver CL, Miranda MB, Shangary S, et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-X(L)-mediated apoptosis resistance[J]. Mol Cancer Ther,2005,4(1):23-31.
[26]Meng Y, Li Y, Li J. et al. (-)-Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells[J]. Leuk Lymphoma,2007, 48(11):2204-2212.
[27]Ko CH, Shen SC, Yang LY, et al. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells[J]. Int J Cancer,2007,121(8):1670-1679.
[28]Huang YW, Wang LS, Chang HL, et al. Effects of serumon (-)-gossypol-suppressed growth in human prostate cancer cells[J]. Anticancer Res,2006,26(5A):3613-3620.
[29]Wolter KG, Wang SJ, Henson BS, et al. Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo[J]. Neoplasia, 2006,8(3):163-172.
[30]Kitada S, Kress CL, Jia L, et al. Bcl-2 antagonist ApoGossypol(NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol(NSC19048)[J]. Blood,2008,111(6):3211-3219.
[31]王瑾,王向红,周淑雅,等.棉籽酚诱导结肠癌细胞系凋亡的作用[J].中国癌症杂志,2000,10(4)：319-322.
[32]Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small2molecule inhibitors of Bcl-2 through structure-based computer screening[J]. J Med Chem,2001,44:4314-4324
[33]Oliver CL, Miranda MB, Shangary S, et al. Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L)-mediated apoptosis resistance[J]. Mol Cancer Ther,2005,4(1):23-31.
[34]Wang X, Wang J, Wong SC, et al. Cytotoxic effect of gossypol on colon carcinoma cells[J]. Life Sci,2000,67(22):2 663-2 671.
[35]梁璐,汪森明,胡喜钢,等.醋酸棉酚对人鼻咽癌细胞凋亡的影响及其作用机制探讨[J].实用医学杂志,2008,24(7)：1 099-1 101
[36]田丹,汪森明,张积仁,等.醋酸棉酚对人宫颈癌细胞增殖的影响及其机制初探[J].解放军医学杂志,2008,33(9)：1 158-1 159
[37]杨金瑞,黄循,杨竹林,等.前列腺增生和前列腺癌组织细胞凋亡及Bcl-2,Bax基 因表达的研究[J].中华泌尿外科杂志,2000,8(21)：485-487.
[38]章劲夫,马杰,曹承华,等.醋酸棉酚诱导鼠前列腺癌细胞凋亡的研究[J].同济大学学报(医学版),2005,26(1)：26-29
[39]Mego M. Telomerase inhibitors in anticancer therapyrgossypol as a potential telomerase inhibitor [J]. Bratisl Lek Listy,2002,103(10):378-381.
[40]Teng CS. Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes[J]. Contracep tion,1995,52(6):389-395.
[41]Balci A, Sahin FI, Ekmekci A. Gossypol induced apoptosis in the human promyelocytic leukemia cell line HL60[J].Tohoku J Exp Med,1999,189(1):51-57.
[42]Carruthers NJ, Dowd MK, Stemmer PM. Gossypol inhibits calcineurin phosphatase activity at multiple sites[J]. Eur J Pharmacol,2007,555(2):106-114.
[43]Zhang M, Liu H, Guo R, et al. Molecularmechanism of gossypol induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells [J]. Biochem Pharmacol,2003,66(1):93-103.
[44]Ergun MA, Konac E, Erbasd, et al. Apoptosis and nitricoxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells[J]. Cell Biol Int,2004,28(3):237-242.
[45]Van Poznak C, Seidman AD, Reidenberg MM, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer:a phase I/II clinical trial [J]. Breast Cancer Res Treat,2001,66(3):239-248.
[46]Chang JS, Hsu YL, Kuo PL, et al. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line[J]. Clin Exp Pharmacol Physiol,2004,31(10):716-722.
[47]Veselska R, Zitterbart K, Auer J, et al. Differentiation of HL-60 myeloid leukemia cells induced by all trans retinoic acid is enhanced in combination with caffeic acid[J]. Int J MolMed,2004,14(2):305-310.
[48]张永清,黄高,陈协群,等.HL-60细胞定向分化时Bcl-2的表达[J].中华血液学杂志,2004,25(9)：569-571.
[49]王文清,黄高,梁蓉等,醋酸棉酚对白血病HL-60细胞凋亡及分化的影响,第四军医大学学报,2006；27(8)：733-736
[50]Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-x(1) [(-)-gossypol] aginst diffuse large cell limphoma[J]. Mol Cancer Ther,2005,4(1):13-21.
[51]Kasten-Pisula U, Windhorst S, Dahm-Daphi J, et al. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis[J]. Radiother Oncol,2007,83(3):296-303.
[52]Xu L,Yang D,Wang S, et al. Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer[J]. Mol Cancer Ther,2005, 4(2):197-205.
[53]Catherine VP, Andrew DS, Marcus MR, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer:A phase I/II clinical trial[J]. Breast Cancer Research and Treatment,2001,66(3):239-248.
[54]Bushunow P, Reidenberg MM, Wasenko J, et al. Gossypol treatment of recurrent adult malignant gliomas[J]. J Neurooncol,1999,43(1):79-86.
[55]Nielsen OS,Judson I,van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas:amulticent rephase II study of the EORTC Soft Tissue and Bone Sarcoma Group[J]. Eur J Cancer,2000,36(1):61-67.
[56]Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy [J]. Clin Oncol,2004,22(8):1480-1490.
[57]Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line t reatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J].J Clin Oncol,1995,13(7):1 537-1 545.
[58]Eemonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas[J]. J Clin Oncol,1993,11(7):1269-1275.
[59]Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults:the EORTC point of view[J]. Crit Rev Oncol/Hematol,1995,20:193-201.
[60]Schutte J, Kellner R, Seeber S. Ifosfamide in the treatment of soft tissue sarcomas: experience at the west german tumor center, Essen[J]. Cancer chemother pharmacol, 1993,31 (Supple2):s194-s198.
[61]Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma[J]. Crit Rev Oncol Hematol,2002,41 (2):157-167.
[62]Kasper B, Ho A D, Egerer G. Is there an indicaton for highdose chemotherapy in the treatment of bone and soft-tissue sarcoma?[J]. Oncology,2005,68(2-3):115-121.
[63]Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas[J]. J Clin Oncol,1993,11(7):1276-1285.
[64]Takeshita H, Kusuzaki K, Ashihara T, et al. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells. J Bone Joint Surg,2000,8(2A):963-969.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |